[Food and Drug Administration extends malignancy warning for TNF-alpha inhibitors].
Harten
P
P
D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002648:Child; D004359:Drug Therapy, Combination; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007938:Leukemia / Q000139:chemically induced*; D008223:Lymphoma / Q000139:chemically induced*; D009369:Neoplasms / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha